Oncology Center of Excellence
Smarter Early Phase Oncology, Delivered
Early Phase oncology trials demand nuanced ethics, complex study designs, and disciplined patient selection – requirements that many generalist CROs aren’t built to support. To translate a novel cancer therapy into meaningful human data, you need specialist oncology leadership from first engagement with regulators through Proof of Concept.
Avance Clinical’s Oncology Center of Excellence (COE) is purpose-built to help biotech sponsors move from first-in-human through Phase II with confidence – combining indication-level expertise, advanced trial design capabilities, and a global site network to keep timelines, budgets, and data quality on track.
GET IN TOUCH WITH OUR
CLINICAL TRIAL EXPERTS
Three decades of experience in biotech drug development
Why Sponsors Choose a Dedicated Oncology COE?
Integrated design support, including adaptive and Bayesian dose-escalation strategies, to optimize dose finding and patient selection in complex solid and haematologic malignancies
Oncology-focused site relationships across the U.S., U.K., EU, and APAC to unlock faster recruitment and access to diverse, often underutilized patient populations
Specialized scientific and regulatory teams experienced with early phase oncology submissions, complex inclusion/exclusion criteria, and evolving global regulatory environments
Senior oncology project leadership and operations to minimize study start up and activation delays, and data quality issues that erode timelines and budgets
Continuity of team and strategy from dose-escalation through expansion and Phase II, enabling efficient data-driven program decisions and smoother geographic scale-up
Avance Clinical + LumaBridge
LumaBridge, Avance Clinical’s specialized, U.S.-based arm, is the Oncology Center of Excellence’s foundation, offering:
- An expansive U.S. footprint
- Deep medical, scientific, and clinical expertise
- Strong site and investigator relationships
Navigating complex clinical and regulatory pathways can be challenging. With our guidance biotech companies can:
- Anticipate regulatory requirements and smoothly navigate FDA procedures
- Pursue the most suitable target population and therapeutic area
- Identify motivated investigators and key opinion leaders
- Quickly adapt to changes in oncology standard of care
- Reach critical milestones efficiently
This combination of Avance Clinical and LumaBridge also makes it even easier for you to access the Phase I market in Australia and New Zealand and then quickly move your oncology innovation into global Phase II and III studies.
Start Smart, Scale With Confidence
With over 260 oncology trials delivered in the last five years, indication-specific experience, and repeat collaborations, Avance Clinical and LumaBridge provide focused Early Phase execution across a broad range of solid and haematologic malignancies — shortening learning curves and enhancing feasibility and protocol design.
Solid Tumors
- Glioblastoma multiforme (GBM)
- Non‑small cell lung cancer
- Hepatocellular carcinoma (HCC)
- Melanoma
- Head and neck cancers
- Solid tumors including renal, breast, colorectal, ovarian, prostate, and all‑comer basket designs
Molecularly Defined/High‑Complexity Programs
- p53‑mutated tumors
- Multi-indication solid tumor programs and novel modalities across RNAi, cell-based therapies, and targeted small molecules (where applicable to your portfolio)
Haematologic Malignancies
- Acute lymphoblastic leukemia (ALL)
- B‑cell non‑Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Myelofibrosis and myeloproliferative neoplasms
- Hodgkin lymphoma
- Haematologic malignancies including B‑cell lymphoid and multiple myeloma
“The Oncology Center of Excellence reflects our commitment to rigorous, Early Phase oncology development. By aligning specialized scientific, regulatory, and operational teams, we help biotech sponsors generate high-quality data earlier, inform decisive go/no-go choices, and prepare for efficient global expansion.” Gabriel Kremmidiotis, Chief Scientific Officer, Avance Clinical
“With Avance Clinical, we offer biotech sponsors a more integrated and efficient pathway to advance important oncology therapies for patients.” George E. Peoples, M.D., FACS, Founder and Executive Chairman, LumaBridge
Partner With the Early Phase Oncology Specialists
Avance Clinical integrates science, sites, and strategy to help you reach critical oncology milestones with greater clarity and speed. From first-in-human design to multi-region expansion, our teams work as an extension of your program to anticipate risk and keep your trials moving.
Meet our expert team
Tina Scheid
Senior Site Specialist
